Clinical Trial Results:
A Phase 2 Open-label, Dose Escalation Study of HST5040 in Subjects with Propionic or Methylmalonic Acidemia Followed by a 6-Month, Randomized, Double-blind, Placebo-controlled, 2-Period Crossover Study and an Open-label, Long-term Extension Study
Summary
|
|
EudraCT number |
2023-000785-33 |
Trial protocol |
Outside EU/EEA |
Global completion date |
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
10 Feb 2024
|
First version publication date |
10 Feb 2024
|
Other versions |
|
Summary report(s) |
2023-000785-33_EudraCT data summary |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.